Evidence map›Paper›PMID 35205680›Full record

ArticleCancers2022

Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC.

Zexuan Liu, Kristin A Altwegg, Junhao Liu, Susan T Weintraub, Yidong Chen, Zhao Lai, Gangadhara R Sareddy, Suryavathi Viswanadhapalli, Ratna K Vadlamudi

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Zexuan LiuDepartment of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, TX 78229, USA.
Kristin A AltweggDepartment of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-3439-0655
Junhao LiuDepartment of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, TX 78229, USA.
Susan T WeintraubDepartment of Biochemistry and Structural Biology, UT Health San Antonio, San Antonio, TX 78229, USA.
Yidong ChenGreehey Children's Cancer Research Institute, UT Health San Antonio, San Antonio, TX 78229, USA.
Zhao LaiGreehey Children's Cancer Research Institute, UT Health San Antonio, San Antonio, TX 78229, USA.
Gangadhara R SareddyDepartment of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, TX 78229, USA.
Suryavathi ViswanadhapalliDepartment of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-7381-6962
Ratna K VadlamudiDepartment of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, TX 78229, USA.
The University of Texas Health Science Center at San Antonio · USCentral South University · CN

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Development of Small Molecule Inhibitor of PELP1 for Treating Advanced Breast CancerF31CA257298 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ALTWEGG, KRISTIN ANN · 2021 to 2022
$51k
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast CancerI01BX004545 · VA · SOUTH TEXAS VETERANS HEALTH CARE SYSTEM · PI VADLAMUDI, RATNA K · 2020 to 2023
–
BLRD VA I01 BX004545National Institute of Health 1F31CA257298NCI NIH HHS F31 CA257298NCI NIH HHS P30 CA054174VA grant I01BX004545
6 · The paper itself

Abstract

The PELP1 oncogene is commonly overexpressed in many cancers, including triple negative breast cancer (TNBC). However, the mechanisms by which PELP1 contributes to TNBC progression are not well understood. To elucidate these mechanisms, we generated CRISPR-Cas9 mediated PELP1 knockout TNBC cell lines, and alterations in the proteome were examined using global data-independent acquisition mass spectrometry (DIA-MS). Further mechanistic studies utilized shRNA knockdown, Western blotting, and RNA-seq approaches. TCGA data sets were utilized for determining the status of PELP1 in TNBC patient tumors and for examining its correlation with ribosomal proteins. Global DIA-MS studies revealed that 127 proteins are upregulated while 220 proteins are downregulated upon PELP1-KO. Bioinformatic analyses suggested that the oncogenic activities of PELP1 involve regulation of expression of ribosomal proteins and ribosomal complexes. RNA-seq studies further suggested PELP1 modulates the functions of transcription factor c-Myc in TNBC. TCGA data confirmed PELP1 has high expression in TNBC patient tumors, and this high expression pattern correlates with c-Myc, a regulator of ribosomal proteins. Collectively, our global approach studies suggest that PELP1 contributes to TNBC progression by modulation of cell cycle, apoptosis, and ribosome biogenesis pathways.

Indexed as

DIA-MSPELP1ribosome biogenesisRNA-seqtriple negative breast cancer

Identifiers

PMID35205680
PMCPMC8924758
OpenAlexW4213004139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.